SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma

Blood

Volumn 111, Issue 4, 2008, Pages 2230-2237

  Chen, Linfeng ^a   Monti, Stefano ^b   Juszczynski, Przemyslaw ^a   Daley, John ^a   Chen, Wen ^a   Witzig, Thomas E ^c   Habermann, Thomas M ^c   Kutok, Jeffery L ^d   Shipp, Margaret A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c MAYO CLINIC   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; R 406; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHOSPHORYLATION; B CELL LYMPHOMA; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 41349110211     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-07-100115     Document Type: Article

References (25)

1. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5:251-262.
2. Gauld SB, Dal Porto JM, Cambier JC. B cell antigen receptor signaling: roles in cell development and disease. Science. 2002;296:1641-1642.
3. Rolli V, Gallwitz M, Wossning T, et al. Amplification of B cell antigen receptor signaling by a Syk/ITAM positive feedback loop. Mol Cell. 2002;10:1057-1069.
4. Monroe JGITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol. 2006;6:283-294.
5. Lam KP, Kuhn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death [see comments]. Cell. 1997;90:1073-1083.
6. Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell. 2004;117:787-800.
7. Smith SH, Reth M. Perspectives on the nature of BCR-mediated survival signals. Mol Cell. 2004:696-697.
8. Wienands J, Larbolette O, Reth M. Evidence for a preformed transducer complex organized by the B cell antigen receptor. Proc Natl Acad Sci U S A. 1996;93:7865-7870.
9. Reth M. Hydrogen peroxide as second messenger in lymphocyte activation. Nat Immunol. 2002;3:1129-1134.
10. Chen L, Juszczynski P, Takeyama K, Aguiar RCT, Shipp MA. Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell receptor signaling and cellular proliferation. Blood. 2006;108:3428-3433.
11. Tonks NK. Redox redux: revisiting PTPs and the control of cell signaling. Cell. 2005;121:667-670.
12. Aguiar R, Yakushijin Y, Kharbanda S, Tiwari S, Freeman G, Shipp M. PTPROt: an alternatively spliced and developmentally regulated B-lymphoid phosphatase that promotes GO/G1 arrest. Blood. 1999;94:2403-2413.
13. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105:1851-1861.
14. Polo JM, Juszczynski P, Monti S, et al. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci U S A. 2007;104:3207-3212.
15. Matsubara S, Koya T, Takeda K, et al. Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation. Am J Respir Cell Mol Biol. 2006;34:426-433.
16. Cha H-S, Boyle DL, Inoue T, et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther. 2006;317:571-578.
17. Wossning T, Herzog S, Kohler F, et al. Deregulation Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells. J Exp Med. 2006;203:2829-2840.
18. Braselmann S, Taylor V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006;319:998-1008.
19. Irish JM, Czenwinski DK, Nolan GP, Levy R. Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood. 2006;108:3135-3142.
20. Budihardjo I, Oliver H, Lutter M, Leo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol. 1999;15:269-290.
21. Irish JM, Czerwinski DK, Nolan GP, Levy R. Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. J Immunol. 2006;177:1581-1589.
22. Rinaldi A, Kwee I, Taborelli M, et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase SYK as a possible therapeutic target in mantle cell lymphoma. Brit J Haematol. 2006;132:303-316.
23. Gururajan M, Jennings CD, Bondada S. Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J Immunol. 2006;176:5715-5719.
24. Gururajan M, Dasu T, Shahidain S, et al. Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth. J Immunol. 2007;178:111-121.
25. Leseux L, Hamdi SM, al Saati T, et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood. 2006;108:4156-4162.